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Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of idiopathic
interstitial pneumonias, characterized by chronic and progressive fibrosis subverting the
lung’s architecture, pulmonary functional decline, progressive respiratory failure, and high
mortality (median survival 3 years after diagnosis). Among themechanisms associated with
disease onset and progression, it has been hypothesized that IPF lungs might be affected
either by a regenerative deficit of the alveolar epithelium or by a dysregulation of repair
mechanisms in response to alveolar and vascular damage. This latter might be related to
the progressive dysfunction and exhaustion of the resident stem cells together with a
process of cellular and tissue senescence. The role of endogenous mesenchymal stromal/
stem cells (MSCs) resident in the lung in the homeostasis of these mechanisms is still a
matter of debate. Although endogenous MSCs may play a critical role in lung repair, they
are also involved in cellular senescence and tissue ageing processes with loss of lung
regenerative potential. In addition, MSCs have immunomodulatory properties and can
secrete anti-fibrotic factors. Thus, MSCs obtained from other sources administered
systemically or directly into the lung have been investigated for lung epithelial repair
and have been explored as a potential therapy for the treatment of lung diseases including
IPF. Given these multiple potential roles of MSCs, this review aims both at elucidating the
role of resident lung MSCs in IPF pathogenesis and the role of administered MSCs from
other sources for potential IPF therapies.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive
fibrosing lung disease of unknown cause that occurs primarily
in older adults with a median survival of 3 years after diagnosis. It
is diagnosed by clinicopathological criteria, including (Raghu
et al., 2011) the radiographic and/or histological hallmark
pattern of usual interstitial pneumonia (UIP). Prognosis
remains extremely poor with most patients dying from
progressive respiratory failure, often precipitated by acute
events, namely disease exacerbations (Collard et al., 2016). As
a therapeutic strategy, the two antifibrotic drugs Pirfenidone and
nintedanib can slow down the respiratory functional decline of
IPF patients, and according both the real-word data and
randomized controlled trials, such as CAPACITY and
ASCEND improve survival in patients (Guenther et al., 2018;
Jo et al., 2017). Despite that, IPF still has a high mortality rate and
that survival times are quite heterogenous (Noble et al., 2011;
Glaspole et al., 2014; Sgalla et al., 2016; Richeldi et al., 2017;
Lederer and Martinez, 2018; Cerri et al., 2019).
The pathogenesis of IPF is complex and far from being
fully understood (Ley et al., 2011; Ryu et al., 2014). Current
hypotheses center on alveolar epithelial and vascular
endothelial injuries that lead to fibroblast activation,
abnormal matrix collagen deposition (King et al., 2011;
Bellaye and Kolb, 2015; Bitterman, 2018), aberrant repair
mechanisms, inflammation, and a regenerative deficit of the
alveolar tissue (Noble et al., 2011; Betensley et al., 2016).
According to more recent studies, the onset and progression
of IPF is due to the aberrant damage and activation of alveolar
epithelial cells (AECs) that lead to the secretion of pro-
fibrotic, coagulant, and inflammatory cytokines controlling
the proliferation, activation and differentiation of fibroblasts
into myofibroblasts and the consequent secretion and
deposition of extracellular matrix (ECM) proteins (Selman
and Pardo, 2020). These mechanisms translate into increased
overall lung structural rigidity and thickening of the alveolar-
capillary barrier with decline in alveolar gas exchange
function. Since current evidence indicates epithelial cells as
primers of disease and myofibroblasts as the key effectors in
perpetrating fibrosis, recent investigations have focused on
the cellular origin of the myofibroblasts including the
potential role of resident mesenchymal progenitors as
major source (Selman and Pardo, 2020). In particular,
among myofibroblasts precursors, lung resident MSCs (LR-
MSCs) have recently been gaining attention as to whether
their aberrant behavior might be crucial in the fibrotic
process (Agha et al., 2014; Enes et al., 2017; Cao et al.,
2019). While research on resident lung MSCs as key
protagonists in the pathogenesis of lung fibrosis is still
emerging, there are many studies focusing on different
roles of MSCs obtained from other sources outside of the
lung namely their therapeutic potential given a range of
immunomodulatory and anti-inflammatory properties
(Uccelli et al., 2008; Mastrolia et al., 2019). To this
purpose, a large number of pre-clinical investigations
demonstrated efficacy of systemically or intratracheally
administered MSCs obtained from bone marrow, adipose
tissue, and other sources in a range of lung injury models.
This has led to consideration and initial clinical
investigations in IPF and other chronic lung diseases.
(Weiss and Ortiz, 2013; Burgess and Irene, 2019). In
parallel, a growing number of clinical investigations have
been exploring systemic MSCs administration for the
potential treatment of acute lung injury including the
acute respiratory distress syndrome (ARDS) as well as
most recently as potential treatment of COVID-19
respiratory failure (Golchin et al., 2020; Meng et al., 2020;
Zumla et al., 2020). Although the mechanism of actions of
MSCs in lung diseases have not yet been fully elucidated, and
are likely to be different depending on the disease, the
beneficial effects seem to be mainly dependent on
paracrine mechanisms including release of bioactive
molecules (soluble proteins, nucleic acids, lipids) and
extracellular vesicles (EVs) (Kim et al., 2012; Chen et al.,
2018; Cruz and Patricia, 2020; Harrell et al., 2019; Beer et al.,
2017; Vizoso et al., 2017). In general, the EVs consists of
exosomes, micro-vesicles (MVs), and apoptotic bodies that
can be discriminated by their size and origin in the cells.
Exosomes contain several molecules such as protein, lipids,
mRNA, miRNA (Valadi et al., 2007), mitochondrial DNA
(Guescini et al., 2010) and others non coding RNAs
(Ferguson and Nguyen 2016). MSCs-derived exosomes
have demonstrated immunoregulatory (Dabrowska et al.,
2021), angiomodulatory (Lee et al., 2013; Alcayaga-
miranda et al., 2016) and anti-apoptotic effects that
control tissue repair and regeneration (Vishnubhatla et al.,
2014; Lou et al., 2017) in both tissue culture and animal
models. This includes a growing literature in which MSCs-
derived EVs can be as effective as the MSCs themselves in pre-
clinical models of lung injuries (Cruz and Patricia, 2020;
Harrell et al., 2019; Beer et al., 2017; Vizoso et al., 2017).
In this dualistic scenario, the aim of this review is to
explore the updated evidence on the molecular
mechanisms of IPF from the alveolar epithelium damage
to fibrotic changes, highlighting the role of resident lung
MSCs as emerging key cellular determinant in IPF onset and
progression and providing an overview of the potential role of
MSCs from different sources and their secretome in cell-
based therapies for lung fibrosis.
KEY MOLECULAR MECHANISMS OF
IDIOPATHIC PULMONARY FIBROSIS AS
AN EPITHELIUM DRIVEN DISEASE
Nowadays IPF is described as an epithelium-driven disease
characterized by aberrant functional epithelium due to aging
and exposure to alveolar injuries in combination with
compromised lung tissue regeneration, leading to abnormal
repair with an imbalance between profibrotic and antifibrotic
factors. Notably, this aberrant reparative mechanism leads to
an increased fibroblast proliferation and myofibroblast activity
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resulting in ECM deposition. It is known that the lung consists
of quiescent tissue with little cell turnover at rest, compared for
example to intestinal epithelial tissues. However, after injury it
has the capability to efficiently regenerate the damage in both
airway and alveolar niches (Beers and Morrisey, 2011). In
normal lung, alveolar injuries are followed by depletion of type
1 alveolar epithelial cells (AECI) that are located at the
interface with vascular endothelium and participate in
alveolar gas exchange function. The lack of AECI is
compensated by the alveolar epithelial cell 2 (AECII) that
normally secrete the pulmonary surfactant to maintain the
surface tension, but also have capacity to proliferate and
differentiate into AECI, restoring the alveolar epithelium
once injured (Fomby et al., 2010). The abnormal reparative
response to injury of epithelial cells in IPF represents an initial
and crucial mechanism of disease. The epithelial secretion of
pro-fibrotic factors promotes fibroblast migration,
proliferation, activation and differentiation into
myofibroblasts with deposition of exaggerated ECM and
subsequently distortion of the lung architecture. Several
mechanisms and molecular pathways in lung IPF
epithelium have been demonstrated to contribute to the
development of the disease. Among these, abnormal AECII
hyperplasia in response to injury results in the formation of
mucus-filled microcystic structures that can evolve into
macrocysts, compromising epithelial differentiation and
alveolar epithelial cell function (Seibold et al., 2013;
Vaughan et al., 2015). Indeed, in the damaged alveolar
epithelium of IPF lungs the process named
“bronchiolization” leads to migration of abnormal basal
cells with accumulation of nuclear β-catenin (basal-cell
hyperplasia) from adjacent bronchioles toward areas of
alveolar injury colonizing them leading to aberrant re-
epithelialization and contributing to disease progression.
The integrity of the alveolar epithelium is severely disrupted
in IPF lungs where abnormal epithelium covering the
fibroblastic foci displayed a bronchiolar immunophenotype
(Chilosi et al., 2003) Different works support the concept that
bronchiolar abnormalities in IPF are due to changes in lung
epithelial cell differentiation (Plantier et al., 2011). In
particular, abnormal basal cells may differentiate into non-
ciliated Club cells or ciliated FoxJ1 expressing bronchial cells,
resulting in bronchiolization of damaged alveoli. Thus,
bronchiolization of enlarged alveolar ducts, cysts and
alveoli, results in the typical honeycombing that can be seen
in the lung of IPF patients (Plantier et al., 2011).
Recently, it has been shown that the oncogene epithelial cell
transforming sequence 2 (ECT2), a guanine nucleotide exchange
factor (GEF) for Rho GTPases, is upregulated in hyperplastic
AECII of IPF patients, and can contribute to the hyperplastic and
proliferative lung epithelial cell phenotype (Ulke et al., 2019). In
addition, pro-fibrotic mediators including transforming growth
factor beta-1 (TGF-β1), platelet-derived growth factor (PDGF),
tumor necrosis factor (TNF), endothelin-1, connective tissue
growth factor (CTGF), osteopontin, and CXC chemokine
ligand 12 (CXCL12) (Pardo et al., 2005; Selman and Pardo,
2020) are up-regulated in AECs and can contribute to the
progression of fibrosis and aberrant extracellular matrix
remodeling.
TGFβ SIGNALING AND CROSS-TALK WITH
WNT AND SONIC HEDGEHOG PATHWAYS
ACTIVATED IN EPITHELIAL CELLS OF
IDIOPATHIC PULMONARY FIBROSIS
PATIENTS
TGFβ can be considered a key regulator of fibrotic process
favoring migration, proliferation, and activation of fibroblasts,
differentiation into myofibroblasts, and deposition of ECM
proteins (Meng et al., 2016; Horowitz and Thannickal, 2019).
Indeed, TGFβ receptor complex activation leads to downstream
canonical (SMAD2 & 3) (Massagué, 2014) and non-canonical
signaling cascades (PI3K, MEK, mTOR, etc) (Hu et al., 2018),
which orchestrate the transcription of profibrotic mediators,
growth factors, microRNAs, and ECM proteins
(Andrianifahanana et al., 2013). Furthermore, cross-talks exists
with TGFβ1 signaling and pathways overexpressed by epithelial
cells of IPF patients such as Wnt and Sonic hedgehog (Shh)
(Bolaños et al., 2012; Cigna et al., 2012). Zhou et al. (2012) found
that TGF-β1 and Wnt/β-catenin crosstalk played a role in IPF
pathogenesis since TGF-β1 activate Wnt/β-catenin pathway and
together with Wnt/β-catenin signaling induced epithelial-
mesenchymal transition and myofibroblast activation (Zhou
et al., 2012). Hasaneen et al.; found that TGF-β1 triggered the
release of a glycosylated transmembrane protein named
EMMPRIN (Extracellular Matrix metalloproteinase Inducer)
that increases the expression of some matrix metalloproteinase
(MMP) and activates β-catenin/canonical Wnt signaling
pathway. Here, EMMPRIN overexpression led to an anti-
apoptotic and pro-fibrotic phenotype in lung fibroblasts of IPF
patients (Hasaneen et al., 2016). Indeed, ICG-001, an inhibitor of
T-cell factor (TCF)/β-catenin transcription, has been shown to
repress TGFβ1-induced EMT and reverse pulmonary fibrosis in
mice (Henderson et al., 2010). More recently, it was demonstrated
that chronic Wnt/β-catenin activity in the IPF lung increased
AECII senescence, leading to further progenitor cells dysfunction
and impaired lung repair (Lehmann et al., 2020). In contrast,
previous studies have shown that a particular lineage of Wnt
responsive alveolar epithelial progenitor cells within the AECII
population acted as a central player in lung regeneration after
acute injury, being able to self-renew (Zacharias et al., 2018).
Bolanos et al. (2012) found that Shh pathway is activated in IPF
lungs and might contribute to IPF pathogenesis by increasing
fibroblast proliferation, migration and ECM production. They
measured the expression of Shh, Patched-1, Smoothened, and
transcription factors glioma-associated oncogene homolog GLI1
and GLI2 in IPF and normal lungs finding that most of themwere
overexpressed in IPF (Bolanos et al., 2012). Further, TGF-β1
modulates the expression of key components of the hedgehog
pathway in lung fibroblasts, while the activity of the transcription
factor GLI from the primary cilium is required to induce and
maintain myofibroblast differentiation (Cigna et al., 2012).
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Among other pathways involved, PDGF showed mitogenic and
chemoattractant effects on fibroblasts while connective tissue
growth factor (CTGF) was found to promote the progression
of fibrosis either activating fibroblasts or through TGF-β pathway
(Allen and Spiteri 2002).
TNF-α, OSTEOPONTIN, CXCL12, AND
MATRIX METALLOPROTEASES
INVOLVEMENT IN THE IDIOPATHIC
PULMONARY FIBROSIS PATHOGENESIS
Tumor necrosis factor-alpha (TNF-α) was found to cause loss
of fibroblast Thy-1 surface expression, thus contributing to
myofibroblast differentiation (Kis et al., 2011). Selman and
Pardo reported that osteopontin acted on both neighboring
epithelial cells and fibroblast to trigger a migratory and
proliferative phenotype (Selman and Pardo, 2020).
Recently CXCL12 was reported to act on CXCR4, which is
expressed in advanced form of interstitial lung diseases,
particularly when cystic lesions are present (Jaffar et al.,
2020). Furthermore, matrix metalloproteases (MMPs)
showed to play a role in the progression of IPF.
Particularly, MMP1 and MMP7 are strongly expressed in
the IPF epithelial cells compared to the epithelium in normal
tissue. MMP1 increases cell proliferation and protects
epithelial cells from apoptosis (Herrera et al., 2013), while
MMP7 is involved in the fibrotic response upon osteopontin
(Pardo et al., 2005). Figure 1 summarizes the different
pathways involved in alveolar epithelial response to lung
injury in normal and IPF lung.
FIGURE 1 | Different response from the epithelium to lung injury in normal and IPF lung. In normal lung, the depletion of alveolar epithelial cells 1 (AECI) that play a
pivotal role in gas exchange with the adjacent blood vessels after injuries, is compensated/replenished by/upon the differentiation of alveolar epithelial cells 2 (AECII) in
AECI, restoring the alveolar epithelium. In lung epithelium of IPF patients, the regeneration of AECI by AECII progenitors is compromised, leading to impaired alveolar re-
epithelialization. Together with the aberrant repair mechanisms the AECs start to secrete pro-fibrotic mediators that through different molecular pathway and down-
stream effectors lead to fibroblast migration, proliferation, activation and differentiation into myofibroblasts with deposition of exaggerated ECM that drastically
compromise the lung biomechanics properties.
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HIPPO PATHWAY IN THE LUNG FIBROSIS
PROGRESSION
It has been reported that Yes-associated protein (YAP) and the
transcriptional coactivator with PDZ-binding motif (TAZ) that
belong to the Hippo pathway are aberrantly activated in lung
fibrosis. In particular, YAP/TAZ that act as sensors of mechanical
forces in cell microenvironment, are activated in fibroblasts of
fibrotic lung due to ECM stiffness thus subjected to mechanical
stretch, leading to the secretion of profibrotic mediators and ECM
proteins (Noguchi et al., 2018; Marchioni et al., 2020). This feed-
forward loop enhances the lung fibrosis progression. Indeed, in
epithelial cells, YAP/TAZ are also activated with the disruption of
cell polarity and increased ECM stiffness in fibrotic tissues
(Noguchi et al., 2018). To this purpose, (Xu et al., 2016b) after
performing single-cell RNA sequencing of epithelial cells from
IPF patients (Xu et al 2016), through Pathway analysis showed
that the YAP/TAZ, TGF-β, Wnt, and PI3K signaling pathways
were aberrantly activated in epithelial cells of IPF lung patients
(Gokey et al., 2018). They suggested that YAP interacted with
mTOR/PI3K/AKT signaling increasing the proliferation and
migration of lung epithelial cells. Then, YAP/TAZ pathway
contributes to the pathogenesis of IPF in lung fibroblasts and
epithelial cells. Recently, Sun and collaborators have shown that
Hippo/TAZ signaling also affects the regenerative capacity of
AECII progenitors. TAZ also named WW Domain Containing
Transcription Regulator 1(WWTR1) plays a crucial role in AECII
to AECI differentiation and thus contribute to the maintenance of
alveolar integrity after injury. Notably, conditional deletion of
TAZ in AECII dramatically reduced AECI regeneration during
recovery leading to exacerbated alveolar lesions and fibrosis in a
bleomycin induced lung injury model. In addition, TAZ signaling
can activate pro-fibrotic responses in fibroblasts (Sun et al., 2019).
Despite all these insights, the complete molecular mechanisms
behind/underlying the differentiation of AECII in AECI after
acute lung injury and how this is dysregulated in IPF are far from
being fully understood.
CELLULAR SENESCENCE, GENETIC AND
ENVIRONMENTAL RISKS IN THE
PATHOGENESIS OF IDIOPATHIC
PULMONARY FIBROSIS
As described above, epithelial damage and activation can drive
myofibroblasts proliferation and the release of pro-fibrotic
factors. What causes initial epithelial damage during the
onset of IPF is not fully understood. To date, an integral
model of IPF pathogenesis has been proposed where the
presence of rare or common gene variants (genetic), cellular
senescence and epigenetic reprogramming, converge to the
initiation and progression of the disease (Michalski and
Schwartz, 2020; Selman and Pardo, 2020). Indeed, aging-
associated alterations as mitochondrial dysfunction and
altered proteostasis could promote epithelial and fibroblast
senescence in IPF lungs through the loss of proteome
integrity and the shortening of telomeres (Mora et al., 2017;
Lederer and Martinez, 2018). Cellular senescence leads to
replicative arrest, apoptosis resistance, and the acquisition of
a senescence-associated secretory phenotype (SASP), that
involves the release of several inflammatory, growth-
regulating and tissue-remodeling factors and could thus
contribute to pro-fibrotic responses (Kirkland and Tchkonia,
2017). Hence, it has been shown that the epithelial cells from
IPF lungs strongly expressed cellular senescence markers p16
and p21 together with an increased secretion of SASP factors as
insulin growth factor binding proteins (Igfbp) 3, 4 and 7 and
MMP 3, 12 and 14 (Lehmann et al., 2017). Then, cellular
senescence, might lead both to exhaustion of stem/progenitor
cell renewal (dysfunction) with loss of regenerative abilities and
to the secretion of pro-inflammatory and matrix-remodeling
cytokines, such as IL-6, TGF-β, and matrix metalloproteases
related to SASP, thus perpetrating fibrosis (Pardo and Moisé s
Selman, 2021). Some of the mechanisms that have been shown
to induce AECII senescence as driver of IPF progression involve
the overexpression of Wnt/β-catenin signaling, DNA damage
and telomere shortening (Mora et al., 2017). Recently, it has
been demonstrated that loss of PTEN (phosphatase and tension
homolog deleted on chromosome ten) triggers senescence in
AECs through the activation of the protein kinase B (Akt)
signaling pathway leading to a reduction of the autophagy. In
particular, in a murine model of bleomycin induced AECs
senescence, repression of Akt2 with the pharmacological
inhibition of the Akt pathway (LY294002 and MK2206),
resulted in ameliorating fibrotic lesions. The cellular
senescence in IPF lungs was then found to be modulated by
Akt/PTEN pathway (Qiu et al., 2019). Recently, Yao and
collaborators have shown the transcriptomic features of
cellular senescence characterizing the AECII isolated from
IPF lung tissue. In particular, they showed how the
conditional loss of Sin3a in adult mouse brought to p53-
dependent cellular senescence of AECII, cell depletion, and
spontaneous and progressive pulmonary fibrosis. The authors
suggested that progressive fibrosis might be caused by
senescence rather than loss of AECII and that targeting of
p53 could block fibrogenesis (Yao et al., 2020). To this
purpose, with the advanced technology of single-cell RNA-
seq, Adams and collaborators identified a new population of
IPF lung epithelial cells that was transcriptionally distinct from
any epithelial cell type previously described in the lung, named
aberrant basaloid cells, characterized by senescence-related
genes including CDKN1A, CDKN2A, CCND1, CCND2,
MDM2, and GDF15 (Adams et al., 2019). Besides the direct
role of senescence of epithelial cells in the progression of IPF, it
has been demonstrated that senescence of lung fibroblasts might
decrease the AECII proliferation and promote migration in
wound healing, affecting the re-epithelialization process after
injury in IPF lung (Blokland et al., 2020). It has been widely
demonstrated that genetic susceptibility together with the
environmental risks play a pivotal role in disease initiation
and progression in both sporadic and familial IPF. In this
context, the most validated and strongest genetic risk factor
for both familial and sporadic IPF, is represented by the single
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nucleotide polymorphism rs35705950 in the promoter region of
the mucin 5B (MUC5B) gene (Steele et al., 2011; Allen et al.,
2017; Allen et al., 2020). Normally, together with mucin 5AC
(MUC5AC), MUC5B plays a crucial role in the muco-ciliary
clearance (MCC) that is essential for removing inhaled debris
and pathogens in the normal lung homeostasis (Roy et al., 2013;
Bonser and Erle 2017). In vivo studies have demonstrated that
full-length murine MUC5B overexpression in AECII of two
lines of C57BL/6 mice resulted in muco-ciliary clearance
dysfunction thus worsening bleomycin-induced lung fibrosis
(Hancock et al., 2018). Indeed, in genetically susceptible
individuals bearing the rs35705950 SNP that cause MUC5B
overexpression and impaired MCC, it might happen that
exposure to inhaled pro-fibrotic particles could compromise
the epithelial repair response to cell injury (Ley et al., 2017).
Genome wide-association studies have revealed several
common and rare variants associated with sporadic and
familial IPF (Fingerlin et al., 2013; Allen et al., 2017; Allen
et al., 2020; Dressen et al., 2018). To this purpose, the common
genetic variants associated with IPF are represented by gene
involved in the airway mucin production (MUC5B, MUC2),
cell-cell adhesion (DSP, DPP9) playing a critical role in the
maintenance of epithelial integrity, innate and adaptive immune
response (Toll-Like receptor signaling, TOLLIP, TLR3),
cytokine and growth factor signaling (IL1RN, IL8, IL4,
TGFβ1), telomere maintenance (TERT, OBFC1) and cell
cycle regulation (KIF15, MAD1L1, CDKN1A, TP53)
(Michalski and Schwartz, 2020).
Rare variants of genes encoding proteins involved in
telomere biology and maintenance have been identified in
about 30% of patients with familial IPF whose AECII are
characterized by short telomeres and proteins for surfactant
production and secretion. These proteins include TERT,
TERC (telomerase RNA component) TINF2 (TERF1
interacting nuclear factor 2), DKC1 (dyskerin), RTEL1,
PARN (poly(A)-specific ribonuclease) and NAF1 (nuclear
assembly factor 1 ribonucleoprotein) (Kropski et al., 2014;
Kropski et al., 2015; Alder et al., 2015; Stuart et al., 2015;
Stanley et al., 2016), SFPTA1, SFPTA2, SFPTC (surfactant
protein A1, A2, C) and ABCA3 (ATP Binding Cassette
Subfamily A Member 3) (Nureki et al., 2018; Doubková
et al., 2019; Takezaki et al., 2019).
Finally, as mentioned above there are environmental risks
such as cigarette smoke, inhalation of wood and metal dust, and
other exposures that might contribute to the onset and
progression of IPF, causing injury in the “genetically
susceptible” patients (Barczyk et al., 2015; Phan et al., 2020;
Shull et al., 2020). Indeed, the environmental risks might
result in epigenomic modifications, with the alteration in key
genes regulation contributing to the pathogenesis of IPF. To this
purpose, exposure of cigarette smoke (CS) triggers DNA damage-
related chromatin binding changes, and alterations in DNA
methylation, influencing gene transcription and the
downstream response of cells to injury (Vaz et al., 2017).
Overall, however, the mechanisms and the correlation between
environmental risk factors, genetic predisposition, aging and IPF
pathogenesis need to be further elucidated.
THE EFFECT OF AGING ON
MESENCHYMAL STROMAL/STEM CELLS
The cellular senescence of MSCs is a cellular mechanism that
compromises their regenerative potential involving the oxidative
state of the cell and mitochondrial dysfunction (Li Y et al., 2017).
Despite lack of complete understanding of the molecular
mechanisms and signaling pathways of senescence in MSCs,
the senescence-associated phenotypes are characterized by an
increase in the SA-β-gal activity, in the G1 cell cycle arrest, in the
reactive oxygen species (ROS) production and expression of p53
and p21 (Jiang et al., 2008) and in a compromised autophagy
process. One effect of MSCs aging can be seen in their decreased
osteogenic activity. The molecular pathway behind the osteogenic
activity is related to the expression of the transcription factor
RUNX2/CBFA1 and the PI3K-AKT pathway that both decrease
with age (Atashi et al., 2015). Additionally, it has been
demonstrated that the adipogenic potential of MSCs tend to
decline with aging and after different passages in in vitro culture
mediated in part through the PPARγmodulation, an adipogenic-
specific transcription and cross-talk with Wnt/β-catenin
signaling pathway (Xu C et al., 2016).
Cellular senescence leads to replicative arrest, apoptosis
resistance, and the acquisition of a senescence-associated
secretory phenotype (SASP), that involves the release of
several inflammatory, growth-regulating and tissue-remodeling
factors and could thus contribute to pro-fibrotic responses
(Kirkland and Tchkonia, 2017). Then, cellular senescence,
might lead both to exhaustion of stem/progenitor cell renewal
(dysfunction) with loss of regenerative abilities and to the
secretion of pro-inflammatory and matrix-remodeling
cytokines, such as IL-6, TGF-β, and matrix metalloproteases
related to SASP, causing persistent fibrosis. (Pardo and Moisé
s Selman, 2021). Indeed, a crucial mechanism that leads to MSCs
senescence is the oxidative stress that leads to the production of
free radicals/ROS (reactive oxygen species) the majority of which
are produced by the mitochondrial respiratory chain (Liu et al.,
2020). From a molecular point of view the p38/MAPK axis
triggers MSCs senescence through ROS production and
accumulation initiating the oxidative process that can lead to
mitochondrial dysfunction, DNA damage and protein damage. In
the endoplasmic reticulum (ER) take place correct folding and
assembling of the proteins into their native conformation prior to
be transported to intracellular organelles or cell surface. In
general, during the ER stress the correct protein folding is
impaired and the unfolded or misfolded proteins accumulate
in the ER lumen compromising the ER homeostasis. Then, the
accumulation of aberrant folded proteins activates as a cellular
protective mechanism, the unfolded protein response (UPR)
ameliorating cell hemostasis and survival during ER stress
process. (Schröder and Kaufman, 2005; Cao and Kaufman,
2012). Indeed, it has been demonstrated that accumulation of
misfolded, or unfolded, proteins into the lumen of ER might
contribute to the progression of age-related diseases (Powers
et al., 2009; López-Otín et al.,). Then, the oxidative stress, with
compromised mechanism of UPR, might cause aging in MSCs
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affecting their cell functions and survival (Geissler et al., 2013;
Wang et al., 2018). Recently, it has been demonstrated that a
deficiency in the UPR lead to inactivation of ATF6, which can
contribute to MSCs aging (Wang et al., 2018). In human MSCs,
ATF6 is involved in cellular proteostasis, the process responsible
for the preservation of a functional proteome and telomere
shortening. The inactivation of ATF6 cause the accumulation
of protein aggregates and compromise the integrity of various
membrane organelles (Wang et al., 2018).
Indeed, these aging-associated alterations, including
mitochondrial dysfunction and altered proteostasis, can also
promote epithelial and fibroblast senescence in IPF lungs
(Lederer and Martinez, 2018; Mora et al., 2017). Conceivable
strategies to prevent aging in MSCs, for example genetic
engineering through the knockdown of the tumor suppressor
p16INK4a/CDKN2A (p16, cyclin-dependent kinase inhibitor 2A,
CDKN2A) might lead to increase of proliferation rate and
clonogenicity of MSCs (Gu et al., 2012). However, these might
also increase the tumorigenesis risks. Finally, the use of growth
factors such as exogenous FGF-2, PDGF and EGF have been
demonstrated to reduce MSCs senescence and increase
proliferation (Gharibi and Hughes, 2012). These might also be
potential therapeutic interventions.
THE ROLE OF RESIDENT LUNG
FIBROBLASTS AND BONE MARROW
PROGENITOR CELLS IN PULMONARY
FIBROSIS
Resident lung fibroblasts represent key effector cells in IPF
pathogenesis since under the action of TGF-β can proliferate
and differentiate into myofibroblasts promoting fibrogenesis and
impairing normal alveolar epithelial repair in response to damage
(David and Cory, 2017; Chanda et al., 2019). Here, the resident
fibroblasts increase the synthesis of collagen and mesenchymal
proteins, such as Vimentin and α-SMA with the activation of
Wnt/β-catenin axis favoring the progression of IPF (Shi et al.,
2017). Then, myofibroblasts, expressing α-SMA, trigger ECM
accumulation and deposition with an increase in the structural
rigidity, decrease in contractility of lung tissue, and impaired
support of alveolar repair (Zhang et al., 1996; Wu and Tang,
2021). According to recent studies, it has been shown that there
are several populations of resident lung fibroblasts including
fibroblasts localized in the lung interstitium adjacent to
alveolar epithelial cells and lipofibroblasts, mainly
characterized by neutral lipids, located adjacent to AECII.
Lipofibroblasts are implicated in alveolar maturation and
surfactant production as well as FGF10 secretion, and have
been shown to modulate the epithelial stem-cell niche in adult
mouse lungs (Alam et al., 2015; Agha et al., 2017). These
lipofibroblasts are characterized by specific markers such as
Sca-1, CD248 (Bartis et al., 2016) and PDGFRα (Iwayama
et al., 2015; Wang et al., 2017). Particularly, PDGFRα allows
the discrimination between interstitial resident fibroblasts and
lipofibroblasts from pericytes, mesenchymal cells closely related
to vascular smooth muscle cells (VSMCs) that underlie and
envelop capillaries, forming focal contacts with adjacent
endothelial cells (Green et al., 2016). Recent studies of lineage
tracing revealed that PDGFRα-expressing interstitial fibroblasts
and/or lipofibroblasts can each differentiate into myofibroblasts
after lung injury and that myofibroblast to lipofibroblast trans-
differentiation is required for fibrosis attenuation in the mouse
lung (El Agha et al., 2017).
As myofibroblasts represent key effector cells in lung fibrosis
due to deposition of collagen and formation of scar tissue, their
cellular origin and potential precursors have been extensively
studied (Hinz et al., 2007; Fernandez and Oliver, 2012; Bochaton-
Piallat et al., 2016; Horowitz and Thannickal, 2019). In this
scenario, several population have been analyzed: 1) resident
lung fibroblasts that under the influence of the profibrotic
microenvironment directly differentiate into myofibroblasts
(Phan 2002), 2) epithelial cells that lose their characteristic
markers (such as E-cadherin and zona occludens-1) and
acquire mesenchymal properties (such as fibroblast-specific
protein-1 and α-SMA expression) in a process named
epithelial-mesenchymal transition (EMT) (Willis et al., 2005;
Kim et al., 2006) 3) bone marrow (BM)-derived cells as
circulating fibrocytes (Phillips et al., 2004; Moore et al., 2005)
and 4) pericytes (Scotton and Chambers, 2007; Wipff et al., 2007;
Hinz, 2012; Hung et al., 2013). While more recent investigations
havemoved away from any significant roles of EMT or circulating
fibrocytes as myofibroblast sources (Rock et al., 2011; Kleaveland
et al., 2014; Barron et al., 2016; Chong et al., 2019), cell-lineage
tracing experiments using reporter mouse models have focused
attention on resident mesenchymal cell populations that can
acquire myofibroblastic phenotype. These include:
- interstitial lung fibroblasts localized in the interstitium
immediately adjacent to alveolar epithelial cells (Angeles,
2015; Barron et al., 2016),
- lipofibroblasts, that are lipid-droplet-containing interstitial
fibroblasts located within close proximity to AECIIs (El Agha
et al., 2017; Alam et al., 2015),
- pericytes localized within the capillary basement membrane
connected to each other and with one or more endothelial cells
(Marriott et al., 2014; Barron et al., 2016),
- mesothelial cells from pleural-mesothelium that line the visceral
and parietal pleural surfaces (Karki et al., 2014), and
- resident lung mesenchymal progenitors (Xie et al., 2016), whose
contribution in myofibroblast differentiating process seems
prevalent.
Since the first isolation and characterization of LR-MSCs from
human transplanted lungs, there has been increasing interest in
their characterization with specific molecular markers for
recognition, their exact location in the lung niche, their role in
regulation of lung tissue homeostasis, and their role in the lung
repair and regeneration after injury (Burgess and Irene, 2019;
Sveiven and Nordgren, 2020). In particular, the expression of
mesenchyme-specific t-box transcription factor (TBX4), that
characterizes early mesenchyme progenitors during embryonic
lung development, correlates with the activation and proliferation
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of myofibroblast accumulation in lung fibrosis. Then, in the adult
lung the TBX4 positive lineage are fibroblasts, smooth muscle
cells, pericytes, and endothelial cells (Xie et al., 2016). Indeed, it
has been shown that the numbers of LR-MSCs decreases during
experimentally induced fibrosis in mice. This cell population has
also been shown to express ATP-binding cassette sub-family G
member 2 (ABCG2) (Jun et al., 2011) and lineage tracing
experiments revealed that ABCG2+ cells are located in
perivascular regions and in proximity of AECI in the mouse
lung. In a bleomycin mouse model ABCG2+ cells are amplified
and significantly transform into myofibroblasts, contributing to
the progression of lung fibrosis (Marriott et al., 2014). Moreover,
another GLI1 (glioma-associated oncogene homolog 1) positive
perivascular lung resident MSCs population has been shown to
contribute to myofibroblast formation in the bleomycin
pulmonary fibrosis mouse model (Kramann et al., 2015).
Recently in a bleomycin mouse model, Cao et al. showed that
Wnt10a had a pivotal role in pulmonary fibrosis as they found an
increased expression level of Wnt10a secreted by LR-MSCs
undergoing myofibroblastic differentiation. Indeed, after
isolation of LR-MSCs with myofibroblast characteristics from
fibrotic lungs they found an increase in Shh pathway activity in
these cells. They demonstrated that the Shh/glioblastoma (Gli)
pathway was a key regulator of LR-MSCs-to-myofibroblast
transition in pulmonary fibrosis. Finally, they showed that the
suppression of the Shh-Wnt signaling prevented myofibroblast
differentiation from LR-MSCs ameliorating pulmonary fibrotic
lesions (Cao et al., 2019).
Furthermore, the role of lipofibroblasts and their contribution to
the myofibroblast cell population in IPF lungs have been studied in
recent works. Among them, in the study from Kheirollhai and
colleagues they demonstrated that the antidiabetic drug, metformin,
inhibits collagen production in primary human lung fibroblasts and
in ex vivo cultured human IPF model and triggers the myo-to
lipofibroblast transdifferentiation leading to a recovery from fibrosis.
They further demonstrated that treatment of bleomycin-injured
mice with metformin resulted in a resolution of fibrosis altering
the fate of myofibroblasts and enhanced their lipogenic
differentiation (Kheirollahi et al., 2019). Finally, they showed that
the antidiabetic drugmetformin had potent antifibrotic effects in the
lung, through the inhibition of TGFβ1 signaling and collagen
formation together with PPARγ signaling activation and
lipogenic differentiation.
In another study from Zysman and colleagues (Zysman et al.,
2020); they investigated whether the cell-cycle inhibitor
p16INK4a limits lung regeneration after newborn
bronchopulmonary dysplasia (BPD), that lead to the arrest of
alveolar development. They found that p16INK4a decrease leads
to an increase of neutral lipid synthesis promoting lipofibroblast
and AECII development within the lung stem-cell niche. Indeed,
they found that treatment with a PPARγ (peroxisome
proliferator-activated receptor γ) agonist increased
lipofibroblast and AECII, restoring alveolar architecture after
hyperoxia-exposure in mice (Zysman et al., 2020). Thus, the
“plasticity” of myofibroblasts that are able under proper
conditions and treatment to transdifferentiate back into
lipofibroblasts, that contribute to the progression of IPF,
provides the possibility to study novel drugs and compound to
revert the fibrotic process in the lung niche.
To date, the emerging picture in the alveolar niche of IPF lung,
indicates that there is a heterogenous myofibroblast population
that may derive from different sources including interstitial lung
fibroblasts, lipofibroblasts, pericytes, mesothelial cells and lung-
resident MSCs rather than from EMT processes/epithelial or BM-
derived cells (Figure 2).
THE ROLE OF LUNG RESIDENT
MESENCHYMAL STROMAL/STEM CELLS
IN LUNG HOMEOSTASIS, INJURY AND
REPAIR
Adult resident stem cells are distributed in organ-specific niches
which provide an appropriate microenvironment that regulates
their development and functionality. Therefore, MSCs of all tissue
origins have a common cellular signature even if there are also
certain molecular features that seem to be organ-specific
including the lung niche (Klein, 2020). In this regard, the
characterization of human LR-MSCs meets the minimal
suggested ISCT criteria for MSCs (Dominici et al., 2006)
including expression of cell surface proteins as CD29, CD73,
CD90, CD105 and CD146 (Kruk et al., 2021) besides being
negative for hematopoietic markers. In vitro differentiation
experiments have further demonstrated multilineage
differentiation of LR-MSCs isolated from central and
peripheral transbronchial biopsies, into adipocytes, osteoblasts
and chondrocytes (Rolandsson et al., 2014). Nevertheless, it has
been reported that LR-MSCs express higher level of FGFR2 as
compared to BM-MSCs in mouse and rats. FGFR2 is bound by
FGF10 leading to LR-MSCs activation and migration (Agha et al.,
2014; Enes et al., 2017). To this purpose, Tong et al.; showed that
in rats intratracheal administration of FGF-10 in lungs, led to LR-
MSCs mobilization that allowed their collection through
bronchoalveolar lavage. The collected LR-MSCs were cultured
in vitro and then intratracheally delivered to rats after LPS-
induced lung injury with more beneficial effects as compared
to BM-MSCs used as positive control (Tong et al., 2016). Then,
Sveiven and Nordgren in a recent review gave an update on both
differences and similarities between BM-MSCs and LR-MSCs
about the surface protein expression profile, the transcriptome,
proteome and secretome (Sveiven and Nordgren, 2020). In
particular, both the transcriptomic data and the pathway
analysis of proteomic data showed that pathways involving
Wnt, elasticity, motility, MET signaling, and integrins were
more up-regulated in LR-MSCs as compared to BM-MSCs.
Among the differences regarding the secretome, it has been
shown that BM-MSCs secreted significantly less monocyte
chemoattractant protein-1 (MCP-1, CCL2), crucial for
macrophage recruitment, than LR-MSCs, while no significant
differences in immunosuppressive effects on lymphocytes were
observed between the two cell populations (Larsson et al., 2016).
In another study comparing murine LR-MSCs and BM-MSCs in
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an elastase-injury mouse model it was suggested that LR-MSCs
displayed prolonged retention in the lungs upon intravenous
administration, which might be attributed to the specific
expression of adhesion molecules (Hoffman et al., 2011). In a
similar elastase model, effects of murine LR-MSCs, BM-MSCs and
adipose derived (AD)-MSCs were compared. All sources reduced
alveolar epithelial and endothelial cell damage and neutrophil
infiltration and increased elastic fiber content (Figure 2). In
contrast to intravenous delivery, intratracheal MSCs
administration further reduced alveolar hyperinflation and
collagen fiber content, while AD-MSCs and LR-MSCs showed a
more significant reduction in fractional area of alveolar collapse
compared to BM-MSCs (Antunes et al., 2014). In 2012 Ricciardi
et al.; showed that LR-MSCs do not significantly differ from human
BM-MSCs with regards to the immunophenotype, stemness gene
profile and mesodermal differentiation potential. Indeed, in vitro
co-culture of either LR-MSCs and BM-MSCs with activated T cells
orNK cells showed the same inhibitory effect of T-cell andNK cells
proliferation from the two different cell lines. They found that
lung-MSCs expressed higher basal level of the nestin marker;
moreover in vitro treatment with retinoic acid showed that the
LR-MSCs led to higher epithelial cell differentiation and
polarization compared to BM-MSCs (Ricciardi et al., 2012). The
authors evaluated the effect of retinoic acid treatment in vitro on
LR-MSCs and BM-MSCs after 4 weeks of RA culture and through
phase-contrast microscopy. While, both LR-MSCs and BM-MSCs
showed a round-cuboid shape as epithelial cells at the end of the
culture, LR-MSCs cultured with RA displayed a stronger
phenotype. Further, after analyzing LR-MSCs by trans epithelial
electric resistance (TEER) assay after RA treatment to measure and
quantify the formation of tight and adherence junctions it was
found a higher polarization tendency in LR-MSCs compared to
BM-MSCs (Ricciardi et al., 2012). Recently, LR-MSCs were isolated
from allografts of human lung transplant recipients (Jarvinen et al.,
2021). In vitro studies demonstrated that these LR-MSCs could
suppress the proliferative capacity of T cells in response to a
mitogenic or an allogeneic stimulus. The authors found that the
immunosuppressive capacity of LR-MSCs was related to the
secretion of PGE2 since it was shown even in the absence of
direct cell contact (Jarvinen et al., 2021).
Among studies aiming at characterizing the functional role of
LR-MSCs, Kruk et al.: showed that human LR-MSCs can also be
forced to differentiate in vitro toward adipocytes (Kruk et al., 2021),
which closely resemble lipofibroblasts that support alveolar epithelial
regeneration by secretion of FGF10 and assist in surfactant
production. Thus, it might be speculated that such events,
depending on cues from the microenvironment, may result in
improved support of alveolar repair. In vitro, LR-MSCs secrete
substantial levels of HFG as well as ECM molecules such as
decorin, which is known to bind and inhibit TGF-β signaling
(Kruk et al., 2021), acquiring of a role in alveolar repair. In vitro
expanded LR-MSCs were also able to engraft decellularized lung
tissue scaffolds and produce growth factors (Kruk et al., 2021).
Concerning the role of LR-MSCs in lung pathologies and in
particular in lung fibrosis several studies highlight a potential
pathological role that is mediated by Wnt signaling. Cao et al.
found that inhibition of the Shh-Wnt pathway in the bleomycin
mouse model prevented LR-MSCs from differentiating into
myofibroblasts and reduced lung fibrosis (Cao et al., 2018).
Summers et al., further report in the same model that genetic
FIGURE2 |Onset andprogression of IPF: themyofibroblast in focus. According to the first hypothesis, the activationof alveolar epithelial cells (AECs) leads to the secretion of
pro-fibroticmolecules, coagulant and cytokines that activate several cells fromdifferent sources: the resident fibroblast, the resident mesenchymal stromal/stem cells, the epithelial
cells that undergo to the epithelial mesenchymal transition, the pericytes and the endothelial cells progenitors. These different cell types in IPF lungs may differentiate into
myofibroblasts with the consequent secretion and deposition of extracellular matrix proteins followed by an overall lung structural rigidity and decline of alveolar function.
According to the most recent publications (Etc 2019; Xie et al., 2016), interstitial lung fibroblasts, pericytes, lipofibroblasts, mesothelial cells and LR-MSCs, whose roles within the
alveolar lung niche are list in the legend within the figure, give rise to the myofibroblast population representing the key cells for the onset and progression of fibrosis.
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activation of Wnt in linage labeled ABCG2 positive pulmonary
mesenchymal vascular progenitor cells (MVPC) drivemicrovascular
dysfunction and exacerbated fibrosis (Summers et al., 2021). In 2011
Jun and collaborators demonstrated that treatment of mice with
bleomycin led to the decrease of endogenous LR-MSCs population
identified as H33342lowCD45neg by flow cytometry and in vivo by
immunostaining to detect the multidrug resistance transporter ATP
binding cassette (ABCG2.) Indeed, they hypothesized that decrease
in the LR-MSCs population favored the progression of fibrosis
measured with Aschroft score inflammation, and pulmonary
arterial hypertension (PAH). The replacement of lung resident
stem cells by intravenous injection of exogenous LR-MSCs
immediately after the intratracheal administration of
bleomycin reduced both the bleomycin-associated fibrosis
and the PAH (Jun et al., 2011). The study from Marriott
et al.; described the functional role of LR-MSCs in IPF. They
found that LR-MSCs were located in the distal lung and
expresses ABCG2 contributing to the myofibroblast
population and lung tissue remodeling in IPF. They found
that in patients with IPF or ILD ABCG2pos cell numbers
were decreased relative to control, possibly because most of
them differentiated into myofibroblasts contributing to the lung
remodeling during IPF (Marriott et al., 2014). In another
functional study, Martin et al. compared LR-MSCs from
donor and IPF patients and found that IPF derived LR-MSCs
presented a decreased genetic profile in the oxidative
phosphorylation pathway and had reduced potential to
induce the repair of a lung epithelial wound in an in vitro
indirect co-culture system (Martin et al., 2020). Thus,
abnormalities in endogenous LR-MSCs may contribute to
aberrant alveolar repair responses in IPF. For their use in
autologous cell-based therapies, more insight into LR-MSCs
function and potential abnormalities in IPF is crucial and may
guide pre-conditioning strategies of LR-MSCs.
Finally, in addition to their molecular and functional properties,
understanding the spatial location of LR-MSCs within the lung is
crucial in order to elucidate their physiological role in maintaining
lung homeostasis. Although the exact location of LR-MSCs remains
under debate, recent studies found that human LR-MSCs express the
so called “HOX code” characteristic of vascular wall MSCs (VW-
MSCs derived from the vascular wall of adult human blood vessels)
therefore pointing at a vascular nature. According to this picture, LR-
MSCswould be locatedwithin two areas: 1. a vascular niche situated at
the perivascular space between the vessels and the surrounding tissue,
and 2. an alveolar niche in close contact with the capillary endothelial
cells and the alveolar epithelial cells (Steens et al., 2021).
To date, given the poor functional characterization of LR-
MSCs related to the bone marrow counterpart, their role in the
lung homeostasis and pathologies should be inferred both
from the studies published on LR-MSCs (Steens et al.,
2021), and essentially from studies based on the comparison
of those to BM-MSCs. Indeed, a deeper characterization of LR-
MSCs, with more in vitro and in vivo studies that will
recapitulate both the spatial location and the functional
effects of these cells in the lung would clarify their role
within lung tissue microenvironment to enrich the
knowledge in the LR-MSCs biology in order to perform
new and effective LR-MSCs-based therapy. (Table 1).
THE ROLE OF EXOGENOUSLY
ADMINISTERED MESENCHYMAL
STROMAL/STEM CELLS IN LUNG REPAIR
AFTER INJURY
MSCs are able to regulate the adaptive and innate immune
systems by either their paracrine effect via soluble factors or
TABLE 1 | In vitro and in vivo studies involving LR-MSCs in lung homeostasis, injury and repair.
Study Method Source of MSCs Outcome










In vitro co-culture and RA treatment LR-MSCs/BM-MSCs ↓ T-cells/NK cells proliferation
↑LR-MSCs polarization after RA treatment
Jarvinen et al.
(2021)




Kruk et al. (2021)1 In vitro studies-differentiation LR-MSCs ↑ HGF,↑ ECM proteins (decorin), ↑ engraftment of decellularized
lung tissue scaffold
Cao et al. (2019) Inhibition of Shh/WNT sigmalling.in bleomycin
model




Knock out mouse model for MVPC Murine MVPC-ABCG2+cells ↑ microvascular dysfunction
↑lung fibrosis
Jun et al. (2011) Intravenous injection of LR-MSCs LR-MSCs ↓ bleomycin-induced fibrosis
↓ arterial hypertension (PAH)
Marriott et al.
(2014)
In vitro functional study/in vivo study bleomycin
mouse model
Human LR-MSCs/ ↓ LR-MSCs cell number in IPF patients
ABCG2+MSC ↑pro-fibrotic reprogramming
Martin et al. (2020) In vitro studies LR-MSCs from donor and IPF
patients
↓ decreased genetic profile in the ox-phospho. Pathway in
LR_MSCs from IPF
↓in vitro repair potential (lung epithelial wound)
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by cell–cell contact mechanisms with inhibition of T-lymphocyte
proliferation, modulation of regulatory T-cells (Tregs) function,
maturation of dendritic cells, reduction of B-cell activation and
proliferation, inhibition of proliferation and cytotoxicity of NK
cells, and stimulation of regulatory T cells (Gharibi and Hughes,
2012; Gao et al., 2016). The paracrine effect of different sources of
MSCs is expressed through the secretion of soluble anti-
inflammatory factors including but not limited to TGF-β,
hepatocyte growth factor (HGF), interleukin (IL)-10, IL-1
receptor antagonist (IL-1Ra) prostaglandin E2 (PGE2)
microRNAs (Vishnubhatla et al., 2014; Gazdic et al., 2015;
Maguire, 2013), and factors that drive endothelial and
epithelial repair and regeneration such as angiopoetin 1
(ANGPT1), FGFs (FGF2, FGF10) keratinocyte growth factor
(KGF)/FGF7, hepatocyte growth factor (HGF), epidermal
growth factor (EGF) and vascular endothelial growth factor
alpha (VEGFA). In addition, MSCs can modulate repair
responses by the deposition and remodeling of extracellular
matrix (Kruk et al., 2021) providing cues to instruct cellular
behavior such as survival, migration and proliferation
(Figure 3).There have been a wide range of MSCs anti-
inflammatory and immunomodulatory properties
demonstrated in preclinical models of lung injuries including
pulmonary fibrosis (Behnke et al., 2020). Although BM-derived
MSCs are the most extensively investigated (Zhang et al., 2019),
MSCs from other sources such as umbilical cord, placenta and
adipose tissue have been studied (Aguilar et al., 2009; Yamada
et al., 2004) (Table 2). As one example, in a bleomycin-induced
lung injury model in mice, Moodley et al.; demonstrated that
umbilical cord derived MSCs (uMSCs) can reduce lung
inflammation and prevent fibrosis by up-regulating anti-
inflammatory modulators and downregulating both cytokine
production and pro-fibrotic factor release as measured through
quantitative real-time PCR from whole lung suspensions from
mice at 14 days post-bleomycin (Moodley et al., 2009). Indeed, in
another study using the bleomycin mouse model of lung fibrosis,
placenta-derived MSCs suppressed the infiltration of neutrophils,
mitigated the inflammatory response and promoted lung tissue
regeneration (Cargnoni et al., 2009; Antoniou et al., 2018).
However, as shown in Table 2, in most of the preclinical
studies, MSCs were administered after a few hours or days
following the induction of lung damage and prevented the
development of fibrotic changes (Jenkins et al., 2017). In
contrast, when MSCs were administered at weeks 8, 10, 12,
and 14 after-BLM induction (Moeller et al., 2008), no effect
on lung collagen content was found while only improvement
in Ashcroft score and lung TGF-β levels was reported. These
studies mirror findings in one of the original studies on MSCs
effects in the bleomycin lung model in which MSCs
administration immediately after bleomycin significantly
reduces inflammation, collagen deposition, and MMPs
activation preventing development of fibrosis whereas delayed
application decreased the inflammation but failed to reduce lung
fibrosis (Ortiz et al., 2003). In another pre-clinical study Yu et al.;
FIGURE 3 | Paracrine effects of MSCs in lung disease. Since theMSCs derived EVs play pivotal roles in different pathways that are common in lung disease, several
works describe the effect of their administration for lung diseases treatment. In general, theMSCs derived EVs display antifibrotic, antiapoptotic, anti-inflammatory effects
and counteract fibrosis with different mechanisms where they can either enhance (green head-arrow) or down-regulate (red head-arrow) growth factors and cytokines
secretion as well as functional activity in lungs (e.g., collagen deposition, mitochondria transfer, etc) as summarized in the cartoon.
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further investigated the mechanism and timing of MSCs
administration in bleomycin-induced pulmonary fibrosis. They
demonstrated that BM-MSCs administration at day 3 and day
6 decreased lung fibrosis and inflammation down-regulating
MMP9, TIMP-1, INF-γ and TGF-β to the same extent as after
day 1 of bleomycin treatment. Thus, they stated that delayed
BM-MSCs administration for up to 6 days after bleomycin
treatment might be effective but did not look at longer
intervals (Yu et al., 2015). Ni et al. demonstrated that in a
humanized mouse model of BLM-induced lung fibrosis,
human BM-MSCs administered at day 2 after bleomycin
injection could prevent the progression of pulmonary
fibrosis suppressing bleomycin-induced human T-cell
infiltration and pro-inflammatory cytokine production
targeting the PD-1/programmed death-ligand 1 pathway.
However, BM-MSCs administration at day 7 after BLM
injection did not improve lung function nor reverse
established fibrosis. The authors concluded that human BM-
MSCs administration displayed anti-fibrotic effects only in the
early phase of BLM induced lung damage, namely the
inflammatory phase (Ni et al., 2018). Taken together, these
studies demonstrate that while MSCs are effective in
mitigating acute lung inflammation and preventing
development of lung fibrosis, they do not reverse
established fibrosis. As IPF is usually diagnosed only after
extensive fibrotic changes are present, this raises questions as
to whether MSCs administration will be beneficial in IPF.
However, in a recent study from Zakaria et al. in albino rats
BM-MSCs systemically administered 28 days after bleomycin-
induction of lung damage; resulted in reversion of established
fibrosis, restored lung architecture, and improved lung
functions (Zakaria et al., 2021). The mechanisms by which
these effects occurred need further study and may open up
better understanding that will support use of systemically
administered MSCs in IPF.
To date, the immunomodulatory effects of systemic or
intratracheal administration of allogeneic and also xenogeneic
MSCs on both the innate and adaptive immune response have
been intensively explored (Masterson et al., 2019). In contrast,
less is known about the interaction of lung resident MSCs with
the immune system and role of LR-MSCs in pathogenesis or
repair from lung injuries.
Finally, along with the beneficial role of exogenous MSCs
administration, there are studies using gene therapy to improve
the MSCs potency for the resolution of lung injury in different
animal models. To this purpose, overexpressing of MSCs with









Li et al. (2017a) Pulmonary fibrosis Human fpMSCs Placenta ↓ collagen deposition, ↑ pro-fibrotic
cytokines









ARDS Human MSCs Umbilical cord ↓ TIMP expression, ↓ lung cytokine, ↑ MMP
expression
1 × 106cells-tail vein-1DAB
Jun et al. (2011) Pulmonary fibrosis Murine MSCs Lung ↓ lymphocyte and granulocyte infiltration,
↓ PAH









↓ TGF-β, ↑ MMP-9,↑ GM-CSF, ↑ IL-1RA 1 × 106cells-tail vein-3DAB
Huleihel et al.
(2017)
Pulmonary fibrosis Human MSCs Bone marrow ↓ collagen deposition and CD45-positive
cells
5 × 105cells-tail vein-7DAB
Ortiz et al. (2003) IPF Murine MSCs Bone marrow ↓ collagen deposition, ↓ inflammation 5 × 105cells-intrajug. 0-7DAB
Ortiz et al. (2007) ILD Murine MSCs Bone marrow ↓ IL-1 and TNF-α 5 × 105cells-intrajug-0DAB
Huang et al.
(2015)
Pulmonary fibrosis Rat MSCs Bone marrow ↓ oxidative stress and collagen deposition 2,5 × 106cells-tail vein -0-7DAB
Lee et al. (2014) ALI Murine MSCs Bone marrow ↓ TGF-β, ↓ IL-1β, ↓ VEGF, ↓ TNF-α, ↓ IL-6,
↓ NOS
1 × 107-tail vein-4DAB
Ono et al. (2015) IPF Human MSCs Bone marrow ↓ endoplasmic reticulum stress, ↓ oxidative
stress, ↓ TGF-β1
5 × 105cells-tail vein-0-1DAB
Lan et al. (2015) IPF Murine MSCs Bone marrow ↓ inflammation, ↑ lung function 5 × 105cells-intratrach-0-3DAB
Cahill et al.
(2016)
IPF Murine MSCs Bone marrow ↓ IL-1β, ↓ apoptosis, ↑ HGF 5 × 104cells-tail vein-6h-9DAB
Kotani T et al.
(2017)
IP Murine ADSCs Adipose tissue ↓ inflammation, ↓ fibrosis 2,5 × 104cells-tail vein-0-7DAB
Lee et al. (2014) IPF Human ADSCs Adipose tissue ↓ fibrosis, ↓ apoptosis, ↓ TGF-β, ↓ epithelial
cell hyperplasia
3 × 105cells-intraper. 0-DAB
Tashiro et al.
(2015)
IPF Murine ADSCs Adipose tissue ↓ oxidative stress, ↓ fibrosis, ↓ apoptosis, ↓
TGF-β, ↓ MMP-2
5 × 105cells-tail vein-1DAB
Yu et al. (2015) IPF Murine MSCs Bone marrow ↑ lung injury repair↓ fibrosis, ↓ INFγ↓ MMP-1
↓ TGF-β, ↓ MMP-9
2.5 × 106cells-tail vein-1,3,6DAB
Rubio et al.
(2017)
IPF Murine MSCs Adipose tissue ↓lung and skin fibrosis, ↓ miR-
199–3p↑CAV-1
5 × 105cells-tail vein-1DAB
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HGF (HGF-MSCs) which is a growth factor with anti-
inflammatory, antiapoptotic, and reparative properties, have
also been tested in acute lung injury models. To this purpose,
MSC-based hepatocyte growth factor (HGF) has been used as
gene therapy for RILI (radiation-induced lung injury). Mice
receiving single dose radiation with 20 Gy of γ rays locally to
the lung and-HGF-modified MSCs (MSCs-HGF) revealed
improved histopathological and biochemical markers of lung
injury. MSCs-HGF reduced secretion and expression of
proinflammatory cytokines, such as TNF-α, interferon-γ,
interleukin (IL)-6, and intercellular adhesion molecule-1,
increasing the expression level of anti-inflammatory cytokine
IL-10 and decreasing the expression levels of profibrotic
factors TGF-β, Col1a1 and Col3a1 culminating in the
reduction of lung fibrosis progression (Wang et al., 2013) In
another study from Chen and collaborators, rat bone marrow-
derived MSCs transfected to express HGF increased MSCs
viability, and inhibit the proinflammatory phenotype of MSCs
in the inflammatory condition. In the rat model of ischemia/
reperfusion I/R-induced lung injury, MSCs-HGF administration
enhanced PaO2 level and ameliorate lung pathological injury,





Given their ability to reduce inflammation and their action on
myofibroblast activity, MSC-derived secretome and EVs have
been increasingly investigated for development of new
therapeutic strategies for lung fibrosis (Worthington and
Hagood, 2020). In bleomycin-induced fibrosis in
immunocompetent CD1 mice, lung spheroid cell-secretome
(LSC-Sec) and exosomes (LSC-Exo) derived from human
LSCs generated from whole lung samples were administered
by inhalation to treat fibrosis progression. Starting at day 10
mice received daily nebulized inhalations for seven consecutive
days with a dose of 10 mg of secretome protein per kg of body
weight or 10 × 109 exosomes particles per kg of body weight or
an equal volume of PBS (Dinh et al., 2020). The results
demonstrated that both LSC-Sec and LSC-Exo treatments
could attenuate and resolve bleomycin-induced lung fibrosis,
restoring normal alveolar structure and decreasing both
collagen accumulation and myofibroblast proliferation.
Indeed, they showed that LSC-Exo reproduced part of the
regenerative potency of the full secretome, while LSC-Exo
overcame MSC-Exo in resolving pulmonary fibrosis and
healthy lung function (Dinh et al., 2020).
Shentu and co-workers demonstrated in in vitro studies that
MSC-derived EVs can play an antifibrotic role demonstrating
down-regulation of TGF-β induced differentiation of isolated
lung fibroblasts into myofibroblast, interaction with resident
myofibroblasts through Thy 1, and delivery of miRNAs
targeting profibrotic genes. To this purpose, MSC-EVs bearing
miR-630, a powerful suppressor of pro-fibrotic genes in lung
fibroblasts, was used to reduce α-SMA expression in lung
fibroblasts (Shentu et al., 2017; Fujita et al., 2018). Mansouri
and collaborators demonstrated that human BM-MSCs-derived
exosomes prevented and reverted experimental pulmonary
fibrosis along with the modulation of monocyte phenotypes in
bleomycin mice model (Mansouri et al., 2019). In particular, they
initially evaluated the preventive effect of a single dose of human
BM-derived MSCs (Mex) administered concurrently with
endotracheal administration of bleomycin in 14-week-old mice
on day 0. The results demonstrated that at day 7, Mex
administration significantly reduced the bleomycin-induced
pulmonary fibrosis and restored collagen content to levels
similar to their bleomycin untreated-counterparts. In parallel
studies, Mex administration at either day 7 or on day 21
decreased collagen content compared to control animals,
although the administration after 21 days was not able to
decrease the Aschroft score (Mansouri et al., 2019). Since it is
known that in lung diseases LR-MSCs can migrate from their
tissue niche toward the alveolar space and can be recovered from
the BAL fluid, LR-MSCs EVs have been isolated from BAL fluid
(Sinclair et al., 2016; Shah et al., 2019). To this purpose, Martin-
Medina et al.; isolated EVs from BALF collected from mice
14 days after intratracheal bleomycin, IPF patients, non IPF
ILD patients, non ILD patients where BALF was performed
for diagnostic evaluation (unclear cough) and ILD was
excluded, and healthy volunteers as controls. The EVs were
then characterized by transmission electron microscopy,
nanoparticle tracking analysis, and Western blotting which
demonstrated increased number of exosomes, according to
their size distribution, in BALF from experimental lung
fibrosis (bleomycin mouse model) and from patients with IPF
compared to patients with non- ILD/non-IPF ILD. Notably, EVs
from IPF BALF stimulated Wnt5A-mediated proliferation of
primary human lung fibroblasts in in vitro studies (Martin-




Clinical studies of MSCs administration in IPF patients to date
have mainly consisted of small phase I safety investigations.
MSCs are known to express major histocompatibility complex
I (MHC I) and lack MHC II expression, a mechanism that allows
them to escape immune host reaction. However, when MSCs are
systemically infused, the high level of procoagulant tissue factor
(TF) expressed might trigger the instant blood-mediated
inflammatory reaction (IBMIR) with potential lethal
consequences for patients. Thus, it has become crucial to find
strategies aiming at modulating MSCs hemocompatibility in
order to increase safety and efficacy of intravascular MSCs
therapies (Moll et al., 2019). Focusing on IPF, the first phase I
trial performed by Tzouvelekis et al.; showed safety of MSCs
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application. This was a phase Ib, non-randomized, open label
clinical trial to study the safety of three endobronchial infusions
of autologous adipose derived stromal cells (ADSCs)-stromal
vascular fraction (SVF) in patients with IPF (n  14) of mild
to moderate disease severity. They showed an acceptable safety
profile with attributable serious short and long-term adverse
events in all patients. However, there was no apparent
suggestion of efficacy and the study was not designed to detect
efficacy (Tzouvelekis et al., 2013). Another phase I safety clinical
trial (AETHER) utilized a single intravenous infusion of
allogeneic BM-MSCs in nine patients with mild to moderate
IPF. No serious adverse events as death, pulmonary embolism,
stroke and hospitalization for worsening dyspnea were observed
through 60 weeks although two deaths occurred because of
progression of IPF. Secondary exploratory end points
demonstrated a decline in % predicted FVC and DLCO below
the defined thresholds for IPF disease progression, however, this
non-controlled trial was not designed to evaluate changes in lung
function (Glassberg et al., 2017). However, as the pre-clinical
data, to date, more strongly suggests a potential beneficial role of
MSCs administration in reducing inflammation and preventing
development of fibrosis rather than reversing established fibrosis,
it would be informative to explore the effect of MSCs
administration in an acute exacerbation of IPF for instance
following a respiratory virus infection. However, to the best of
our knowledge there are not as yet pre-clinical studies based on
the induction of experimental respiratory virus infection in mice




There are multiple potential roles of MSCs in lung fibrosis. On
one hand, given the lessons learned from preclinical studies,
further strategies can be developed in which exogenously
administered MSCs might contribute to prevent disease
progression or might even revert established lung fibrosis,
suppressing inflammation and supporting alveolar repair.
This will involve further clarification on the route and timing
of MSCs administration, source and age of MSCs administered
and other factors that have thus far given rise to the
heterogeneous results of available preclinical data. On the
other hand, lung resident MSCs might contribute to IPF
pathogenesis and progression as they might differentiate into
myofibroblast following lung damage. Moreover, whereas the
role of LR-MSCs in lung fibrosis pathology is still being
elucidated, it remains presently unknown whether healthy
LR-MSCs could potentially restore/rescue this function. Since
the microenvironment to which MSCs are exposed seems to
regulate function and to affect further cellular development, it is
arguable that healthy LR-MSCs might have a therapeutical effect
in terms of lung regeneration. Thus, further work on
characterizing MSCs from different sources, including LR-
MSCs, in terms of function, phenotype and secretome will
contribute to a greater understanding of the mechanism of
disease in the aim of developing specialized and targeted
approaches to treat lung fibrosis. Furthermore, besides the
characterization of different MSCs sources, the gene therapy
based on a deeper knowledge of molecular scenario of MSCs
after their administration, would improve their potency and
potentiate their effect to treat specific disease.
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GLOSSARY
IPF idiopathic pulmonary fibrosis
IIPs idiopathic interstitial pneumonias
MSCs mesenchymal stem cells
ECT2 epithelial cell transforming sequence 2
AECI alveolar epithelial cells 1
AECII alveolar epithelial cell 2
AEP alveolar epithelial progenitor
TGF-β1 transforming growth factor beta 1
PDGF platelet-derived growth factor
VEGF vascular endothelial growth factor
FGF fibroblast growth factor
IL-1 interleukin 1
TNF-α tumor necrosis factor-alpha
ERS endoplasmic reticulum stress
EMMPRIN extracellular matrix metalloproteinase inducer
CXCL12 C-X-C motif chemokine 12
CCL2 chemokine C-C motif ligand 2
EMT epithelial mesenchymal transition
α-SMA alpha smooth-muscle actin
Shh sonic hedgehog
PTEN phosphatase and tensin homologuephosphatase and TENsin
homolog
INFγ interferon γ
PDGFRα platelet-derived growth factor receptor A
ABCA3 ATP binding cassette subfamily A member 3
DKC1 dyskerin pseudouridine synthase 1
TP53 tumor protein P53




hMSCs human mesenchymal stem cells
KGF keratinocyte growth factor
ARDS acute respiratory distress syndrome
Thy-1 or CD90 cluster of differentiation 90
BAL bronchoalveolar Lavage
SASP senescence associated secretory phenotype
uMSCs umbilical cord derived Mesenchymal Stem Cells
DLCO diffuse lung coefficient for carbon dioxide
Igfb insulin growth factor binding protein
FVC forced vital capacity
CT computed tomography
ADMSCs adipose tissue-derived mesenchymal stem cells
GEF guanine nucleotide exchange factor
CTGF connective tissue growth factor
EV extracellular vesicles
PI3K phosphatidylInositol 3-Kinase
TCF T cell factor
miRNA micro RNA
MVs micro vesicles
MHC I major histocompatibility complex I
HGF hepathocyte growth factor
IDO-1 indolamine 2,3-dioxygenase-1
IL-1Ra IL-1 receptor antagonist
PGE2 prostaglandin E2
PTEN phosphatase and tensin homologuephosphatase and TENsin
homolog
NK natural killer cells
YAP yes-associated protein
TAZ transcriptome coactivator with PDZ-binding motif
ECs endothelial cells
GLI1 transcription factors glioma-associated homologue
MHC-1 major histocompatibility complex I
BLM bleomycin
CS cigarette smoke
SFPTA1 surfactant protein 1
CDKN1A cyclin dependent kinase inhibitor 1A
TERT telomerase reverse transcriptase
MCC mucociliary clearance
MCP1 CCL2 monocyte chemotacticprotein 1
SDF1 stromal cell-derived factor 1
TIMP tissue inhibitors of metalloproteinase
BDNF brain-derived neurotrophic factor
NGF nerve growth factor
CINC-1 cytokine-induced neutrophil chemoattractant 1
AT-MSCs adipose tissue-derived mesenchymal stem cells
COPD chronic obstructive pulmonary disease
LSC-Sec lung spheroid cell-secretome
LSC-Exo lung spheroid cell exosomes
lncRNAs long non coding RNA
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